TaiRx, Inc. (TPEX:6580)

Market Cap	1.67B -48.7%
Revenue (ttm)	15.46M +190.6%
Net Income	-141.99M
EPS	-1.29
Shares Out	110.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,092
Average Volume	155,275
Open	15.15
Previous Close	15.15
Day's Range	14.45 - 15.15
52-Week Range	14.35 - 31.80
Beta	0.16
RSI	21.09
Earnings Date	Apr 10, 2026

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2024, TaiRx's revenue was 8.22 million, an increase of 61.79% compared to the previous year's 5.08 million. Losses were -138.84 million, -34.60% less than in 2023.